Mannose triflate

P001
Grade:
GMP product
Tested for bioburden and bacterial endotoxins
Description:
Chemical precursor for the synthesis of ¹⁸F-FDG (Fludeoxyglucose), the most widely used radiopharmaceutical in positron emission tomography (PET).
It is applied in oncology for diagnostics, TNM staging, and dynamic monitoring of various types of malignant tumors.
Synonyms:
1,3,4,6-Tetra-O-acetyl-2-O-trifluoromethanesulfonyl-β-D-mannopyranose, TATM
Molar weight:
480 g/mol (net substance)
Molecular formula:
C₁₅H₁₉F₃O₁₂S (net substance)
CAS №:
92051-23-5
PubChem CID:
11113597
Retest date:
Not less than 18 months from the manufacturing date
Packaging:
2R/4ml or 8R/10ml Type I glass vials with bromobutyl rubber stoppers
Storage conditions:
–20 ±5 °C
Transportation at 2–8 °C (less than 1 month)
Available quantities:

0.1 mg; 1.0 mg; custom quantity upon request

Quality parameters

Quality parameters

Appearance: White solid
Identification:
– HPLC: Retention time of main peak corresponds to that of TATM reference standard
– Mass spectrometry: m/z = 480.4 ± 4
Residual heavy metals (ICP-OES): ≤ 100 ppm
Purity (HPLC): ≥ 99.5%
Bacterial endotoxins (gel-clot method): ≤ 10.0 EU/vial
Bioburden (microbial enumeration tests):
– TAMC ≤ 10² CFU/vial
– TYMC ≤ 10¹ CFU/vial
Bioburden tests are performed for non-sterile products.
Other products